News 2025-01-03
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
Porton Pharma Solutions Ltd. is pleased to announce its achievement of a score of 44 out of 100 in the 2024 S&P Global Corporate Sustainability Assessment. This marks an improvement of 6 points compared to the previous assessment, with advancements observed across all three dimensions. (CSA Score as of November 27, 2024).
In the latest assessment, Porton’s scores increased by 3 points in the Environmental dimension, 5 points in the Social dimension, and 9 points in the Governance & Economic dimension. Significant progress was noted in areas such as Transparency and Reporting, Materiality, Climate Strategy, Labor Practices, Human Rights, and Supply Chain Management.
Guided by the ESG principles of "Green Development, Promoting Common Progress, Building a Healthy Society, and Enhancing Corporate Governance," Porton is dedicated to embedding ESG values into its corporate strategy and operations. In 2024, Porton further strengthened its ESG management by implementing various initiatives, including developing management systems, setting targets, and enhancing the quality of disclosures. Moving forward, Porton remains committed to practicing ESG principles and fostering sustainable development.
Others
More
News 2026-09-30
Porton Newsletter - September, 2026 Recap
Porton Recognized by LyncBio Therapeutics for ADC Payload-Linker CMC Capabilities Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001 PMO Therapeutics: Technical Review and Manufacturing Platform Capabilities

News 2026-09-29
Porton Recognized by LyncBio Therapeutics for ADC Payload-Linker CMC Capabilities
Porton, as the project's CDMO partner, completed process development and manufactured non-GMP toxicology batches and GMP clinical trial materials for LYNC-101's payload-linker.